Treatment of neuroblastoma stage 4 with 131I-meta-iodo- benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study

European Journal of Cancer

Volumn 34, Issue 9, 1998, Pages 1398-1402

  Klingebiel, T ^a   Bader, P ^a   Bares, R ^b   Beck, J ^a   Hero, B ^c   Jurgens H ^c   Lang, P ^a   Niethammer, D ^a   Rath, B ^c   Handgretinger, R ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NONE

Author keywords

High dose chemotherapy; Immunotherapy; mIBG; Neuroblastoma stage 4

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GUANIDINE DERIVATIVE; IODINE 131; MELPHALAN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; NEUROBLASTOMA; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0032145478     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00130-0     Document Type: Article

References (24)

1. 1. Berthold F, Burdach S, Kremens B, et al. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin Pädiatr 1990, 202, 262-269.
2. 2. Berthold F, Trechow R, Utsch S, et al. Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Ped Hem Oncol 1992, 14, 207-215.
3. 3. Castel V, Garcia-Miguel P, Melero C, et al. The treatment of advanced neuroblastoma. Results of the Spanish Neuroblastoma Study Group (SNSG) studies. Eur J Cancer 1995, 31A, 642-645.
4. 4. Kushner B, Gulati SC, Kwon JH. High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor risk neuroblastoma. Cancer 1991, 68, 242-247.
5. 5. Philip T, Ladenstein R, Lasset C, 1070 myeloablative procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. Eur J Cancer 1997, 33, 2130-2135.
6. 6. Philip T, Ladenstein R, Zucker JM, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993, 67, 119-127.
7. 7. Negrier S, Michon J, Floret D, et al. Interleukin 2 and lymphokine activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 1991, 9, 1361-1370.
8. 8. Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report of the Children's Cancer Study Group. J Clin Oncol 1994, 12, 2382-2389.
9. 9. Klingebiel T, Treuner J, Ehninger G, et al. Metaidodobenzylguanidine in the treatment of metastatic neuroblastoma: clinical, pharmacological acid dosimetric aspects. Cancer Chemother Pharmacol 1989, 25, 143-148.
10. 10. Klingebiel T, Berthold F, Treuner J, et al. Metaidobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German neuroblastoma trial. Med Pediatr Oncol 1991, 18, 84-88.
11. 131I-m]IBG. Prog Clin Biol Res 1994, 385, 309-317.
12. 12. Klingebiel T, Handgretinger R, Herter M, et al. Peripheral blood stem cells (PBSC) as stem cell source in children and young adults after myeloablative treatment - comparison between GM-CSF and G-CSF for mobilization. J Hematotherapy 1995, 4, 307-314.
13. 13. Handgretinger R, Bader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2 Cancer Immunol Immunother 1992, 35, 199-204.
14. 14. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995, 31(A), 261-267.
15. 15. Berthold F. Studie zur Behandlung des Neuroblastoms im Kindesalter NB 90, Köln, 1990.
16. 16. Brodeur GM, Pritchard J, Berthold F, et al. Revision of the international criteria for neuroblastom diagnosis, staging, and response to treatment. Prog Clin Biol Res 1994, 385, 363-369.
17. 17. Handgretinger R, Greil J, Schürmann U, et al. Positive selection and transplantation of autologous peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematotherapy 1997, 6, 235-242.
18. 18. Ladenstein R, Urban C, Gadner H, et al. First experience with prognostic factors in unselected neuroblastoma patients. The Austrian Neuroblastoma 87 Study. Eur J Cancer 1995, 31(A), 637-641.
19. 131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 1991, 35, 244-247.
20. 20. Parisi MT, Matthay KK, Huberty JP, et al. Neuroblastoma: dose related sensitivity of MIBG scanning in detection. Radiotherapy 1992, 184, 463-467.
21. 131I]Metaiodobenzylguanidine, high-dose melphalan and total body irradiation with bone marrow rescue: feasibility of a new strategy for advanced neuroblastoma. Eur J Cancer 1995, 31(A) 252-256.
22. 123I-m]IBG. Nuklearmedizin 1992, 31, 209-212.
23. 23. McCowage GB, Vowels MR, Shaw PJ, et al. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, cisplatin, and total body irradiation. J Clin Oncol 1995, 13, 2789-1795.
24. 24. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group Studies. J Clin Oncol 1996, 14, 2417-2426.